JURISDICTION REPORT: TAIWAN
BIOTECH AND MEDICAL INVENTIONS: MOVING THE GOAL POSTS
Crystal Chen and Phoebe Yeh Tsai Lee & Chen
Te Amendment to the Taiwan Patent Act is expected to come into effect in November 2012. As the government endeavours to stimulate the growth of the biotech and pharmaceutical industries in Taiwan, many new rules will be implemented.
Biological materials deposit Taiwan is not a signatory to the Budapest Treaty, and the current and the new Patent Act both require a patent applicant for biological materials to make a deposit in Taiwan regardless of whether the biological materials have been deposited in a foreign depository already. Tere are instances, however, that would allow a patentee to avoid making a domestic deposit. As well as circumstances in which a person of ordinary skill in the art can easily obtain the materials, a domestic deposit can be exempted if the applicant has already deposited biological materials in a country which has reciprocal recognition with Taiwan. At the moment there is no foreign depository that recognises the effect of deposits in Taiwan, but the inclusion of this rule may implicate any possible bilateral recognition in the future.
Te general rule under the current Patent Act is to make a deposit prior to the filing date of a patent application. If the applicant has made a deposit in an International Depositary Authority (IDA) recognised under the Budapest Treaty prior to filing a patent application in Taiwan, a three- month grace period will be granted for making a domestic deposit and submitting a certificate to the Taiwan Intellectual Property Office (TIPO). Pursuant to the new Patent Act, a lenient time period of four months from the application date or 16 months from the earliest priority date will be granted to the applicants.
Patent term extension Te current patent term extension is applicable for an invention patent involving pharmaceuticals and agrichemicals, or their preparation processes, and that is subject to regulatory approval under other laws, if this approval takes more than two years from the publication of a patent. Te two-year threshold requirement is removed from the new Patent Act so that, as long as regulatory approval is obtained aſter the publication of a patent, the patentee may be able to obtain an extension of the patent term for a period of not more than five years. It is noted that regulatory approval may only provide a one-time basis for an extension of the patent term, and the subject of the extended patent term shall be limited to effective ingredients and usage identified in the regulatory approval.
Patent exemption for generic drug testing Generic drug testing will no longer be an issue for patent infringement. Te new Patent Act exempts the testing of generic drugs from the exclusive right of a patent, if the purpose of the testing is obtaining regulatory approval.
www.worldipreview.com
“THE NEW PATENT ACT WILL EXEMPT THE DIRECT OR INDIRECT IMPLEMENTATION OF INVENTION PATENTS SUCH AS TESTING DRUGS AND MEDICAL DEVICES DURING BOTH PRE-CLINICAL AND CLINICAL TRIALS.”
Te scope of patent exemption includes research, trials and necessary acts performed for the purpose of obtaining regulatory approvals for new products, or obtaining marketing permits for foreign products. Terefore, for the purpose of obtaining pharmaceutical approval or permits, the new Patent Act will exempt the direct or indirect implementation of invention patents such as testing drugs and medical devices during both pre-clinical and clinical trials, as well as offers for sale, sales and imports.
Compulsory licence for pharmaceuticals Following the World Trade Organization’s Doha Declaration on the TRIPS Agreement and Public Health, the new Patent Act stipulates compulsory licence provisions for pharmaceuticals. To facilitate access to pharmaceuticals for HIV/AIDS, tuberculosis, malaria or other epidemics afflicting populations in many developing and underdeveloped countries, the TIPO may grant an applicant a compulsory licence to practise a patent in order to supply an amount of pharmaceuticals needed by a particular country. However, negotiations with patentees involving reasonable conditions and time frames are a prerequisite for the grant of a compulsory licence, unless the patented pharmaceutical is already a subject of a compulsory licence in the recipient country. A compulsory licensee shall pay reasonable compensation to a patentee.
Crystal J. Chen is an attorney at law and partner at Tsai Lee & Chen. She can be contacted at:
cjchen@tsailee.com.tw
Phoebe S.H. Yeh is a patent attorney and the head of biochemical group at Tsai Lee & Chen. She can be contacted at:
info@tsailee.com.tw
World Intellectual Property Review March/April 2012 63
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76